XML 48 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
RECEIVABLES
 12 Months Ended
Dec. 31, 2023
Accounts Receivable, after Allowance for Credit Loss [Abstract]  
RECEIVABLES RECEIVABLES
 December 31,
Dollars in millions20232022
Trade receivables$9,551 $8,848 
Less charge-backs and cash discounts(646)(675)
Less allowance for expected credit loss(23)(22)
Net trade receivables8,882 8,151 
Alliance, royalties, VAT and other2,039 1,735 
Receivables$10,921 $9,886 

Non-U.S. receivables sold on a nonrecourse basis were $1.0 billion in 2023, $1.0 billion in 2022 and $1.5 billion in 2021. In the aggregate, receivables from three pharmaceutical wholesalers in the U.S. represented approximately 72% and 66% of total trade receivables at December 31, 2023 and 2022, respectively.

Changes to the allowances for expected credit loss, charge-backs and cash discounts were as follows:
 Year Ended December 31,
Dollars in millions202320222021
Balance at beginning of year$697 $744 $663 
Provision(a)
9,158 7,476 7,257 
Utilization(9,186)(7,521)(7,170)
Other— (2)(6)
Balance at end of year$669 $697 $744 
(a)    Includes provision for expected credit loss of $14 million in 2023, $7 million in 2022 and $4 million in 2021.